In order to target GBM, recombinant human epidermal growth factor (EGF) [68], EGFR monoclonal antibody (McAb) cetuximab (C225) [87], CTX [85], heat shock protein Hsp70 [70], hydrophilic peptide I6P7 [80], polypeptide tLyP-1 [81], and the serine protease Granzyme B (GrB) [83] have also been reported to modify iron oxide NPs. Here, GZMB is linked to glioblastoma.